SEC Company Response from Atara Biotherapeutics, Inc. (ATRA) (CIK 0001604464) (ATRA) — Jul 21, 2014
Atara Biotherapeutics, Inc. (ATRA) (CIK 0001604464)
Date: July 21, 2014 · CIK: 0001604464 · Accession: 0001193125-14-273903
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-196936
Letter
Goldman, Sachs & Co.
200 West Street,
New York, New York 10282
Citigroup Global Markets Inc.
388 Greenwich Street
New York, New York 10013
July 21, 2014
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Jeffrey Riedler
Johnny Gharib
Daniel Greenspan
Re: Atara Biotherapeutics, Inc.
Registration Statement on Form S-1
Registration File No. 333-196936
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933 (the “Act”), we, as representatives of the several Underwriters, hereby join in the request of Atara Biotherapeutics, Inc. (the “Company”) for acceleration of the effective date of the above-named Registration Statement so that it becomes effective at 4:00 PM Eastern Daylight Time on July 23, 2014, or as soon thereafter as practicable.
Pursuant to Rule 460 under the Act, we, as representatives of the several Underwriters, wish to advise you that we have effected the following distribution of the Company’s Preliminary Prospectus dated July 10, 2014:
(i) Dates of distribution: July 10, 2014 through the date hereof
(ii) Number of prospective underwriters to which the preliminary prospectus was furnished: 3
(iii) Number of copies of the preliminary prospectus furnished to investors: approximately 2,851
(iv) Number of copies of the preliminary prospectus distributed to others, including the Company, the Company’s counsel, independent accountants, and underwriters’ counsel: approximately 52
We, the undersigned, as representatives of the several Underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934.
Very truly yours,
GOLDMAN, SACHS & CO.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Goldman, Sachs & Co. 200 West Street, New York, New York 10282 Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 July 21, 2014 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jeffrey Riedler Johnny Gharib Daniel Greenspan Re: Atara Biotherapeutics, Inc. Registration Statement on Form S-1 Registration File No. 333-196936 Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933 (the “Act”), we, as representatives of the several Underwriters, hereby join in the request of Atara Biotherapeutics, Inc. (the “Company”) for acceleration of the effective date of the above-named Registration Statement so that it becomes effective at 4:00 PM Eastern Daylight Time on July 23, 2014, or as soon thereafter as practicable. Pursuant to Rule 460 under the Act, we, as representatives of the several Underwriters, wish to advise you that we have effected the following distribution of the Company’s Preliminary Prospectus dated July 10, 2014: (i) Dates of distribution: July 10, 2014 through the date hereof (ii) Number of prospective underwriters to which the preliminary prospectus was furnished: 3 (iii) Number of copies of the preliminary prospectus furnished to investors: approximately 2,851 (iv) Number of copies of the preliminary prospectus distributed to others, including the Company, the Company’s counsel, independent accountants, and underwriters’ counsel: approximately 52 We, the undersigned, as representatives of the several Underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934. Very truly yours, GOLDMAN, SACHS & CO. CITIGROUP GLOBAL MARKETS INC. Acting severally on behalf of themselves and the several Underwriters By: GOLDMAN, SACHS & CO. By: /s/ David McDonald Name: David McDonald Title: Managing Director By: CITIGROUP GLOBAL MARKETS INC. By: /s/ Jennifer Jarrett Name: Jennifer Jarrett Title: Managing Director [Signature Page to Underwriters’ Acceleration Request]